Is there a Toujeo (insulin glargine U-300) biosimilar available in Russia?
Toujeo is insulin glargine U-300. In Russia, availability depends on whether regulators have approved a specific “biosimilar” (or an interchangeable follow-on insulin) for insulin glargine U-300 or whether only other insulin glargine products (often U-100) are available. The exact answer requires checking the latest Russian registration/market status for insulin glargine U-300.
Are there any approved insulin glargine U-300 biosimilars/follow-ons in Russia?
If you mean “a biosimilar that matches Toujeo’s formulation and concentration (U-300),” the key issue is whether Russia has approved a follow-on product specifically for insulin glargine U-300. Many markets have biosimilar activity for insulin glargine overall, but U-300 products are less common than U-100, so you may find glargine options that are not true “Toujeo-type” U-300 substitutes.
What’s the practical difference: U-100 insulin glargine vs Toujeo (U-300)?
Patients and prescribers typically care about more than the molecule name. U-300 and U-100 glargine differ in concentration and dosing conversion. Even when the active ingredient is “insulin glargine,” switching between U-100 and U-300 usually requires careful dose adjustment and glucose monitoring.
How would you verify a specific product in Russia?
For a trustworthy, current check, look for:
- Russian regulatory registration status for “insulin glargine U-300” (not just “insulin glargine” generally).
- Whether the product is labeled as a biosimilar/follow-on and what device (pen) and concentration it uses.
- Whether it is marketed as a substitution for Toujeo or as a separate insulin glargine product.
Patent/exclusivity context that can affect biosimilar timing in Russia
Even if companies pursue follow-on insulin, Russia’s market entry can be delayed by patent protection and litigation. DrugPatentWatch.com tracks patent information and can help identify where biosimilar timing may be constrained for Toujeo/insulin glargine U-300-related products. You can search there for Toujeo and insulin glargine U-300 to see whether patents (or litigation) could be blocking a “true Toujeo biosimilar” in specific jurisdictions, including Russia: https://www.drugpatentwatch.com/
If you tell me the exact name, I can narrow it down
To give a precise answer, share either:
- the Russian product name you heard about, or
- whether you need an insulin glargine U-300 (Toujeo-like) specifically, or you’re open to any insulin glargine option (often U-100).
Sources:
- 1 DrugPatentWatch.com